APO RESEARCH · REPORT
Tuberculosis Vaccine Treatment
Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
Product & engineering
Understand the product.
Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.
Selected research
Industry Research
Tuberculosis Vaccine Treatment Industry Research Report 2026
Market perspective
Tuberculosis Vaccine is a vaccine primarily used against tuberculosis. Tuberculosis is a serious infection, which affects the lungs and other parts of the body, such as the bones, joints and kidneys. The bacille Calmette-Guérin (BCG) vaccine has existed for 80 years and is one of the most widely used of all current vaccines, reading >80% of neonates and infants in countries where it is part of the national childhood immunization programme.
Besides, BCG Vaccine is also used to treat a certain type of bladder cancer. Bladder cancer is the growth of abnormal or cancerous cells on the inner lining of the bladder wall. BCG helps prevent the cancer from coming back in the bladder lining, and also reduces the risk of it becoming invasive.
In the last several years, global market of Tuberculosis Vaccine Treatment developed smoothly, with an average growth rate of 0.73%.
Read the full market overview
The classification of Tuberculosis Vaccine Treatment includes Immune Vaccine and Therapy Vaccine, and the proportion of Immune Vaccine in 2019 is about 99.66%.
Tuberculosis Vaccine Treatment is widely sold through Self-Procurement, UNICEF and Other. The most proportion of Tuberculosis Vaccine Treatment is sold through Self-Procurement, and the proportion in 2019 is 62.14%.
Asia-Pacific is the largest consumption place, with a consumption market share nearly 45% in 2019. Following Asia-Pacific, Middle East and Africa is the second largest consumption place with the consumption market share of 35.66%.
Market competition is intense. Merck, Japan BCG Lab, Serum Institute of India are the leaders of the industry, they occupy the 60% of the market.
Report Scope
This report quantifies the global Tuberculosis Vaccine Treatment market in terms of revenue (US$ million) and, where applicable, sales volume (K Dose), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Dose) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Tuberculosis Vaccine Treatment Market by Company
Merck
Japan BCG Lab
Serum Institute of India
AJ Vaccines
BioFarma
GreenSignal Bio Pharma
China National Biotec
Biomed Lublin
Taj Pharmaceuticals
Ataulpho de Paiva
IVAC
Queen Saovabha Mem. Inst
Microgen
Tuberculosis Vaccine Treatment Segment by Type
Immune Vaccine
Therapy Vaccine
Tuberculosis Vaccine Treatment Segment by Application
Self-Procurement
UNICEF
Other
Tuberculosis Vaccine Treatment Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis Vaccine Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis Vaccine Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis Vaccine Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Tuberculosis Vaccine Treatment manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Tuberculosis Vaccine Treatment by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Tuberculosis Vaccine Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Immune Vaccine
- Therapy Vaccine
Applications
- Self-Procurement
- UNICEF
- Other
Companies covered
- Merck
- Japan BCG Lab
- Serum Institute of India
- AJ Vaccines
- BioFarma
- GreenSignal Bio Pharma
- China National Biotec
- Biomed Lublin
- Taj Pharmaceuticals
- Ataulpho de Paiva
- IVAC
- Queen Saovabha Mem. Inst
- Microgen
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Tuberculosis Vaccine Treatment Market Size (2021-2032)
- 2.2.2 Global Tuberculosis Vaccine Treatment Sales (2021-2032)
- 2.2.3 Global Tuberculosis Vaccine Treatment Market Average Price (2021-2032)
- 2.3 Tuberculosis Vaccine Treatment by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Immune Vaccine
- 2.3.3 Therapy Vaccine
- 2.4 Tuberculosis Vaccine Treatment by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Self-Procurement
- 2.4.3 UNICEF
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Tuberculosis Vaccine Treatment Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Tuberculosis Vaccine Treatment Sales (K Dose) of Manufacturers (2021-2026)
- 3.3 Global Tuberculosis Vaccine Treatment Revenue of Manufacturers (2021-2026)
- 3.4 Global Tuberculosis Vaccine Treatment Average Price by Manufacturers (2021-2026)
- 3.5 Global Tuberculosis Vaccine Treatment Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Tuberculosis Vaccine Treatment, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Tuberculosis Vaccine Treatment, Product Type & Application
- 3.8 Global Manufacturers of Tuberculosis Vaccine Treatment, Established Date
- 3.9 Global Tuberculosis Vaccine Treatment Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Merck
- 4.1.1 Merck Company Information
- 4.1.2 Merck Business Overview
- 4.1.3 Merck Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Merck Tuberculosis Vaccine Treatment Product Portfolio
- 4.1.5 Merck Recent Developments
- 4.2 Japan BCG Lab
- 4.2.1 Japan BCG Lab Company Information
- 4.2.2 Japan BCG Lab Business Overview
- 4.2.3 Japan BCG Lab Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Japan BCG Lab Tuberculosis Vaccine Treatment Product Portfolio
- 4.2.5 Japan BCG Lab Recent Developments
- 4.3 Serum Institute of India
- 4.3.1 Serum Institute of India Company Information
- 4.3.2 Serum Institute of India Business Overview
- 4.3.3 Serum Institute of India Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Serum Institute of India Tuberculosis Vaccine Treatment Product Portfolio
- 4.3.5 Serum Institute of India Recent Developments
- 4.4 AJ Vaccines
- 4.4.1 AJ Vaccines Company Information
- 4.4.2 AJ Vaccines Business Overview
- 4.4.3 AJ Vaccines Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 AJ Vaccines Tuberculosis Vaccine Treatment Product Portfolio
- 4.4.5 AJ Vaccines Recent Developments
- 4.5 BioFarma
- 4.5.1 BioFarma Company Information
- 4.5.2 BioFarma Business Overview
- 4.5.3 BioFarma Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 BioFarma Tuberculosis Vaccine Treatment Product Portfolio
- 4.5.5 BioFarma Recent Developments
- 4.6 GreenSignal Bio Pharma
- 4.6.1 GreenSignal Bio Pharma Company Information
- 4.6.2 GreenSignal Bio Pharma Business Overview
- 4.6.3 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 GreenSignal Bio Pharma Tuberculosis Vaccine Treatment Product Portfolio
- 4.6.5 GreenSignal Bio Pharma Recent Developments
- 4.7 China National Biotec
- 4.7.1 China National Biotec Company Information
- 4.7.2 China National Biotec Business Overview
- 4.7.3 China National Biotec Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 China National Biotec Tuberculosis Vaccine Treatment Product Portfolio
- 4.7.5 China National Biotec Recent Developments
- 4.8 Biomed Lublin
- 4.8.1 Biomed Lublin Company Information
- 4.8.2 Biomed Lublin Business Overview
- 4.8.3 Biomed Lublin Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Biomed Lublin Tuberculosis Vaccine Treatment Product Portfolio
- 4.8.5 Biomed Lublin Recent Developments
- 4.9 Taj Pharmaceuticals
- 4.9.1 Taj Pharmaceuticals Company Information
- 4.9.2 Taj Pharmaceuticals Business Overview
- 4.9.3 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Taj Pharmaceuticals Tuberculosis Vaccine Treatment Product Portfolio
- 4.9.5 Taj Pharmaceuticals Recent Developments
- 4.10 Ataulpho de Paiva
- 4.10.1 Ataulpho de Paiva Company Information
- 4.10.2 Ataulpho de Paiva Business Overview
- 4.10.3 Ataulpho de Paiva Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Ataulpho de Paiva Tuberculosis Vaccine Treatment Product Portfolio
- 4.10.5 Ataulpho de Paiva Recent Developments
- 4.11 IVAC
- 4.11.1 IVAC Company Information
- 4.11.2 IVAC Business Overview
- 4.11.3 IVAC Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 IVAC Tuberculosis Vaccine Treatment Product Portfolio
- 4.11.5 IVAC Recent Developments
- 4.12 Queen Saovabha Mem. Inst
- 4.12.1 Queen Saovabha Mem. Inst Company Information
- 4.12.2 Queen Saovabha Mem. Inst Business Overview
- 4.12.3 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Queen Saovabha Mem. Inst Tuberculosis Vaccine Treatment Product Portfolio
- 4.12.5 Queen Saovabha Mem. Inst Recent Developments
- 4.13 Microgen
- 4.13.1 Microgen Company Information
- 4.13.2 Microgen Business Overview
- 4.13.3 Microgen Tuberculosis Vaccine Treatment Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Microgen Tuberculosis Vaccine Treatment Product Portfolio
- 4.13.5 Microgen Recent Developments
5 Global Tuberculosis Vaccine Treatment Market Scenario by Region
- 5.1 Global Tuberculosis Vaccine Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Tuberculosis Vaccine Treatment Sales by Region: 2021-2032
- 5.2.1 Global Tuberculosis Vaccine Treatment Sales by Region: 2021-2026
- 5.2.2 Global Tuberculosis Vaccine Treatment Sales by Region: 2027-2032
- 5.3 Global Tuberculosis Vaccine Treatment Revenue by Region: 2021-2032
- 5.3.1 Global Tuberculosis Vaccine Treatment Revenue by Region: 2021-2026
- 5.3.2 Global Tuberculosis Vaccine Treatment Revenue by Region: 2027-2032
- 5.4 North America Tuberculosis Vaccine Treatment Market Facts & Figures by Country
- 5.4.1 North America Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
- 5.4.3 North America Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Tuberculosis Vaccine Treatment Market Facts & Figures by Country
- 5.5.1 Europe Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
- 5.5.3 Europe Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Tuberculosis Vaccine Treatment Market Facts & Figures by Country
- 5.6.1 Asia Pacific Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Tuberculosis Vaccine Treatment Market Facts & Figures by Country
- 5.7.1 South America Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
- 5.7.3 South America Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Tuberculosis Vaccine Treatment Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Tuberculosis Vaccine Treatment Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Tuberculosis Vaccine Treatment Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Tuberculosis Vaccine Treatment Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Tuberculosis Vaccine Treatment Sales by Type (2021-2032)
- 6.1.1 Global Tuberculosis Vaccine Treatment Sales by Type (2021-2032) & (K Dose)
- 6.1.2 Global Tuberculosis Vaccine Treatment Sales Market Share by Type (2021-2032)
- 6.2 Global Tuberculosis Vaccine Treatment Revenue by Type (2021-2032)
- 6.2.1 Global Tuberculosis Vaccine Treatment Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Tuberculosis Vaccine Treatment Revenue Market Share by Type (2021-2032)
- 6.3 Global Tuberculosis Vaccine Treatment Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Tuberculosis Vaccine Treatment Sales by Application (2021-2032)
- 7.1.1 Global Tuberculosis Vaccine Treatment Sales by Application (2021-2032) & (K Dose)
- 7.1.2 Global Tuberculosis Vaccine Treatment Sales Market Share by Application (2021-2032)
- 7.2 Global Tuberculosis Vaccine Treatment Revenue by Application (2021-2032)
- 7.2.1 Global Tuberculosis Vaccine Treatment Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Tuberculosis Vaccine Treatment Revenue Market Share by Application (2021-2032)
- 7.3 Global Tuberculosis Vaccine Treatment Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Tuberculosis Vaccine Treatment Value Chain Analysis
- 8.1.1 Tuberculosis Vaccine Treatment Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Tuberculosis Vaccine Treatment Production Mode & Process
- 8.2 Tuberculosis Vaccine Treatment Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Tuberculosis Vaccine Treatment Distributors
- 8.2.3 Tuberculosis Vaccine Treatment Customers
9 Global Tuberculosis Vaccine Treatment Analyzing Market Dynamics
- 9.1 Tuberculosis Vaccine Treatment Industry Trends
- 9.2 Tuberculosis Vaccine Treatment Industry Drivers
- 9.3 Tuberculosis Vaccine Treatment Industry Opportunities and Challenges
- 9.4 Tuberculosis Vaccine Treatment Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst